此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (EP2991637) FENFLURAMINE FOR USE IN THE TREATMENT OF DRAVET SYNDROME
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准
Claims

1. A formulation comprising fenfluramine or a pharmaceutically acceptable salt thereof for use in the treatment of Dravet syndrome,
wherein the formulation is for oral administration, and
wherein said treatment comprises administration of fenfluramine as a monotherapy, as the sole therapeutic agent.
  2. The formulation for use according to Claim 1, wherein the treatment comprises the treatment of a patient diagnosed with Dravet syndrome, who exhibits a mutation in one, some or all of the genes selected from the group consisting of SCN1 A, SCN1 B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD and PCDH19.
  3. The formulation for use according to Claim 1 or Claim 2, wherein the dose of fenfluramine is less than 0.5 mg/kg/day to 0.01 mg/kg/day.
  4. The formulation for use according to any of Claims 1-3, wherein the formulation is a liquid formulation.